Tiotropium+olodaterol Respimat® with exercise training and behaviour modification significantly increased exercise capacity compared to placebo1,2 PHYSACTO® trial data also showed improvements in shortness of breath associated with physical activity for people taking tiotropium+olodaterol Respimat® compared to placebo1 Even in early chronic obstructive pulmonary disease (COPD) stages, decreasing activity is a strong predictor of disease worsening and increases the risk of disability and death3,4
(